Vaginal estradiol use and the risk for cardiovascular mortality

Human Reproduction

Volumn 31, Issue 4, 2016, Pages 804-809

  Mikkola, Tomi S ^a,b   Tuomikoski, Pauliina ^a,b   Lyytinen, Heli ^a,b   Korhonen, Pasi ^c   Hoti, Fabian ^c   Vattulainen, Pia ^c   Gissler, Mika ^d   Ylikorkala, Olavi ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b FOLKHÄLSAN RESEARCH CENTER   (Finland)

^c EPID Research Oy   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

cardiovascular death; coronary heart disease; estrogen; myocardial infarction; stroke; topical vaginal estrogen

Indexed keywords

ESTRADIOL; AGENTS USED INTRAVAGINALLY; CARDIOVASCULAR AGENT; DELAYED RELEASE FORMULATION; ESTROGEN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FINLAND; FOLLOW UP; GROUPS BY AGE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RISK ASSESSMENT; RISK REDUCTION; ADMINISTRATION AND DOSAGE; CORONARY DISEASE; DELAYED RELEASE FORMULATION; FEMALE UROGENITAL DISEASES; MIDDLE AGED; MORTALITY; PRESCRIPTION; REGISTER; RISK FACTOR; STROKE; THERAPEUTIC USE;

AGED; CARDIOVASCULAR AGENTS; COHORT STUDIES; CORONARY DISEASE; DELAYED-ACTION PREPARATIONS; DRUG PRESCRIPTIONS; ESTRADIOL; ESTROGENS; FEMALE; FEMALE UROGENITAL DISEASES; FINLAND; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; REGISTRIES; RISK FACTORS; STROKE; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84963962018     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dew014     Document Type: Article

References (33)

1. Ameye L, Antoine C, Paesmans M, de Azambuja E, Rozenberg S. Menopausal hormone therapy use in 17 European countries during the last decade. Maturitas 2014; 97: 287-291
2. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women s Health Initiative randomized controlled trial. J Am Med Assoc 2004; 291: 1701-1712
3. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, Bluhm E, Connelly S, Hubbell FA, Lane D et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women s Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012; 13: 476-486
4. Chester AH, Jiang C, Borland JA, Yacoub MH, Collins P. Oestrogen relaxes human epicardial coronary arteries through non-endothelium-dependent mechanisms. Coron Artery Dis 1995; 6: 417-422
5. Collins P, Shay J, Jiang C, Moss J. Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation 1994; 90: 1964-1968
6. Committee on Practice Bulletins-Gynecology. Management of gynecological issue in women with breast cancer. Obstet Gynecol 2012; 119: 666-682
7. El Khoudary SR, Wildman RP, Matthews K, Thurston RC, Bromberger JT, Sutton-Tyrrell K. Endogenous sex hormones impact the progression of subclinical atherosclerosis in women during adverse cardiovascular events: nationwide cohort study. Br Med J 2012; 344: e1802
8. Eurostat Causes of death statistics. http: //epp.eurostat.ec.europa.eu/statistics-explained/index.php/Causes-of-death-statistics (25 June 2015, date last accessed)
9. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-941
10. International Menopause Society Consensus Statement. TheWriting Group on behalf of the Workshop Consensus Group. Aging, menopause, cardiovascular disease and HRT International Menopause Society Consensus Statement. Climacteric 2009; 12: 368-377
11. Jane FM, Davis S.R. A practitioner s toolkit for managing the menopause. Climacteric 2014; 17: 564-579
12. Labrie F, Cusan L, Gomez J-L, Cö té I, Bérubé R, Bélanger P, Martel C, Labrie C. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009; 16: 30-36
13. Lahti RA, Sarna S, Penttilä A. Exploitation of autopsy in determining natural cause of death: trends in Finland with special reference to the diagnostics of ischemic heart diseases and cerebrovascular diseases in middle-Aged males, 1974-1993. Forensic Sci Int 1998; 91: 109-121
14. Lehto HR, Lehto S, Havulinna AS, Ketonen M, Lehtonen A, Kesäniemi YA, Airaksinen KJ, Salomaa V. Sex differences in short- and long-Term case-fatality of myocardial infarction. Eur J Epidemiol 2011; 26: 851-861
15. Lokkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard O. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008; 29: 2660-2668
16. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006; 108: 1354-1360
17. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012; 7: CD004143
18. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308: 1583-1587
19. Meretoja A, Kaste M, Roine RO, Juntunen M, Linna M, Hillbom M, Marttila R, Erilä T, Rissanen A, Sivenius J et al. Trends in treatment and outcome of stroke patients in Finland from 1999 to 2007. PERFECT Stroke, a nationwide register study. Ann Med 2011; 43(Suppl 1): S22-S30
20. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53: 605-619
21. Naessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol. Am J Obstet Gynecol 1997; 177: 115-119
22. Naessen T, Rodriguez-Macias K, Lithell H. Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. J Clin Endocrinol Metab 2001; 86: 2757-2762
23. North American Menopause Society. 2013 position statement of The North American Menopause Society Management of symptomatic vulvovaginal atrophy. Menopause 2013; 902: 903-904
24. Olie V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 2010; 5: 457-463
25. Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, Olivera CK, Abed H, Balk EM, Murphy M. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014; 124: 1147-1156
26. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women s Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321-233
27. Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 2015; 18: 1-14
28. Smith NL, Blondon M, Wiggins KL, Harrington LB, van Hylckama Vlieg A, Floyd JS, Hwang M, Bis JC, McKnight B, Rice KM et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. J Am Med Assoc Intern Med 2014; 174: 25-31
29. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006; 4: CD001500
30. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ. Treatment of symptoms of themenopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 3975-4011
31. Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause. 2011; 18: 385-392
32. Tuomikoski P, Ebert P, Groop PH, Haapalahti P, Hautamäki H, Rönnback M, Ylikorjala O, Mikkola TSM. Effect of hot flushes on vascular function: a randomized controlled trial. Obstet Gynecol 2009; 114: 777-785
33. Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola TSM. Coronary heart disease mortality and hormone therapy before and after theWomen s Health Initiative. Obstet Gynecol 2014; 124: 947-953